摘要
目的:探讨肿瘤标志物在印巢肿瘤诊断中的价值。方法:随机抽取1999年1月-2002年12月我院收治的卵巢肿瘤患者105例,根据病理分类进行分组,回顾性分析其血清 AFP、CEA、血清铁蛋白(SF)、CA125、CA19-9、CA15-3水平,利用 SAS 统计分析系统分别评价其在卵巢肿瘤诊断中的价值。结果:①卵巢癌患者血清中 CA125、CA15-3、SF 含量明显高于良性肿瘤患者(P<0.01).恶性组 CA19-9含量明显高于良性组(P<0.05).AFP 和 CEA 含量在两组之间差异无显著性(P>0.05);②单项指标以 CA125的诊断性能最好,其次为 CA15-3、CA19-9、SF;③Ⅲ～Ⅳ期卵巢癌患者血清中 CA125、CA15-3、SF 含量及阳性率均高于Ⅰ～Ⅱ期卵巢癌患者(P<0.01),CA19-9在两组患者中差异无显著性(P>0.05);④上皮性卵巢癌患者血清中 CA125的阳性率高于非上皮性印巢癌患者,差异具显著性(P<0.05),其余差异无显著性(P>0,05);⑤指标联合检测时,在全部不同指标组合中,以 CA125、CA15-3、CA19-9、SF 4项中任意2项阳性作为卵巢恶性肿瘤的判断有较好的诊断性能;在3项指标联合检测中,以 CA125、CA19-9、SF 指标组合诊断性能最好。结论:CA125、CA15-3、CA19-9和 SF 可以作为卵巢良恶性肿瘤的鉴别和恶性肿瘤预后判断的指标。
Objective To explore the values of tumor markers in the diagnosis of ovarian tumors. Methods One hundred and five cases of ovarian tumors were collected and divided into the benign group and the malignant group. The levels of tumor markers, including AFP, CEA, SF, CA125, CA19-9 and CA15-3, were determined and then analysed by SAS statistical software. Results The levels of CA125, CA15-3 and SF were significantly higher in the patients with malignant ovarian tumors than those in the patients with benign tumors （P〈0.01）. The level of CA19-9 in the ovarian cancer was significantly higher than that in the benign subjects （P〈0.05）. There was no difference in the AFP and CEA levels between the benign group and the malignant group （P〉0.05）. The positive rates of CA125, CA15-3 and SF in the patients with stage Ⅲ and Ⅳ were higher than those in the patients with stage Ⅰ and Ⅱ （P〈0.01）. In the all markers, the diagnostic value of CA125, as a single index, was the best. The combination of CA125, CA19-9 and SF was superior to any other markers for the diagnosis of ovarian cancers. Conclusions CA125, CA19-9, CA153 and SF could be used as indicators in distingushing benign from malignant ovarian tumors and in evaluating the prognosis of malignaut ovarian tumors.
出处
《诊断学理论与实践》
2005年第5期400-402,共3页
Journal of Diagnostics Concepts & Practice
关键词
卵巢肿瘤
肿瘤标志物
诊断
Ovarian tumor
Diagnosis
AFP
CEA
SF
CA125
CA19-9
CA15-3
